Table 3.
IL-10 and IL-12 serum expression in chronic liver disease with HCV infection.
| +ve HCV-chronic liver disease∗∗∗ | −ve HCV-chronic liver disease | NDC | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PCH | LC | HCC | Total | PCH | LC | HCC | Total | ||
| IL-10 (ng/mL)∗ |
6.437 ± 0.518 |
14.49 ± 0.615 |
16.39 ± 1.015 |
13.169 ± 4.02 |
6.6 ± 1.13 |
13.0 ± 0.14 |
15.4 ± 1.16 |
12.61 ± 3.95 |
6.04 ± 0.568 |
|
| |||||||||
| IL-12 (ng/mL)∗∗ |
484.875 ± 16.23 |
501.86 ± 19.1 |
656.45 ± 17.1 |
549.27 ± 79.15 |
499.0 ± 22.63 |
533.5 ± 2.12 |
658.25 ± 27.035 |
587.3 ± 79.5 |
258.4 ± 14.06 |
∗IL-10 expression showed significant difference in HCV-infected (P < 0.0001) and noninfected patients (P < 0.003) compared to nondisease control.
∗∗IL-12 expression showed significant difference in HCV-infected and noninfected patients (P < 0.0001) compared to nondisease control.
∗∗∗+ve HCV-chronic liver disease shows that there is asymptotic significance (P < 0.0001) within groups (Kruskal-Wallis test) and the difference between groups was detected by Mann-Whitney showing that there is a significant (P < 0.0001) difference between each group and the other one.